SavedAdd your journal

Journals / Turkish Journal of Rheumatology(.)Archives of Rheumatology / 2011 / Cilt: 26 - Sayı: 2

Simvastatin Tedavisine Yanıtlı Hiperimmünoglobulin D ve Periyodik Ateş Sendromlu Bir Adölesan

An Adolescent with Hyperimmunoglobulinemia D and Periodic Fever Syndrome Responding to Simvastatin Treatment

Elif AYDINER KARAKOÇ
Cevdet ÖZDEMİR
Sevgi KELEŞ
Safa BARIŞ
Nerin N. BAHÇECİLER
Işıl B. BARLAN
Pages
167–170
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This treatment is thought to reduce the recurrent fever attacks by reducing the mevalonic acid increase or isopreniod shortage.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The hyperimmunoglobulinemia D and periodic fever syndrome is proposed to be caused by a defect in the activity of mevalonate kinase enzyme which is involved in cholesterol and non-sterol isoprenoid biosynthesis.
📊
Key Findings & Data:In this article, we present our therapeutic approach with the hypolipidemic agent, simvastatin, in a 12-year-old boy followed up with a diagnosis of hyperimmunoglobulinemia D and periodic fever syndrome.
💡
Conclusion & Impact:This treatment is thought to reduce the recurrent fever attacks by reducing the mevalonic acid increase or isopreniod shortage.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The hyperimmunoglobulinemia D and periodic fever syndrome is proposed to be caused by a defect in the activity of mevalonate kinase enzyme which is involved in cholesterol and non-sterol isoprenoid biosynthesis. This autosomal recessive inherited auto- inflammatory syndrome is characterized by recurrent fever attacks, abdominal pain, lymphadenopathy, skin lesions and joint involvement. In this article, we present our therapeutic approach with the hypolipidemic agent, simvastatin, in a 12-year-old boy followed up with a diagnosis of hyperimmunoglobulinemia D and periodic fever syndrome. Simvastatin treatment of an adolescent with hyperimmunoglobulinemia D and periodic fever syndrome unresponsive to anti-inflammatory strategies has resulted in a favorable outcome. This treatment is thought to reduce the recurrent fever attacks by reducing the mevalonic acid increase or isopreniod shortage.

Özet

Hiperimmünoglobulin D ve periyodik ateş sendromu kolesterol ve izoprenoid biyo-sentezinde görev alan mevalonat kinaz enzimindeki kusura bağlı olarak ortaya çıkmaktadır. Bu otozomal resesif kalıtımla geçmiş olan oto-inflamatuvar sendrom tekrarlayan ateş atakları, karın ağrısı, lenfadenopati, cilt lezyonları ve eklem tutulumu ile karakterizedir. Bu yazıda periyodik ateş ve hiperimmünoglobulin D sendromu tanısı ile kliniğimizde izlenmekte olan 12 yaşındaki bir erkek çocuğunda hipolipidemik ajan simvastatin ile uyguladığımız tedavi yaklaşımı sunuldu. Hiperimmünoglobulin D ve periyodik ateş sendromu olan ve diğer antiinflamatuvar tedavilere yanıt vermeyen bir adölesanda simvastatin tedavisi ile klinik düzelme gözlendi. Bu tedavinin mevalonik asit artışını veya izoprenoid azlığını engelleyerek tekrarlayan ateş ataklarını azalttığı düşünüldü.

🔖

Cite This Article

KARAKOÇ, E. A., ÖZDEMİR, C., KELEŞ, S., BARIŞ, S., BAHÇECİLER, N. N., BARLAN, I. B. (2011). Simvastatin Tedavisine Yanıtlı Hiperimmünoglobulin D ve Periyodik Ateş Sendromlu Bir Adölesan. Turkish Journal of Rheumatology(.)Archives of Rheumatology, Cilt: 26 - Sayı: 2, 167–170. https://ajindex.com/articles/376099

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (7)

  1. Haas D, Hoffmann GF. Mevalonate kinase deficiencies: from mevalonic aciduria to hyperimmunoglobulinemia D syndrome. Orphanet J Rare Dis 2006;1:13. Houten SM, Frenkel J, Waterham HR. Isoprenoid biosynthesis in hereditary periodic fever syndromes and inflammation. Cell Mol Life Sci 2003;60:1118-34.
  2. Attout H, Guez S, Ranaivo I, Jameerbaccus N, Series C. A patient with hyper-IgD syndrome responding to simvastatin treatment. Eur J Intern Med 2008;19:e82-3. Simon A, Drewe E, van der Meer JW, Powell RJ, Kelley RI, Stalenhoef AF, et al. Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin Pharmacol Ther 2004;75:476-83.
  3. Drenth JP, Haagsma CJ, van der Meer JW. Hyperimmunoglobulinemia D and periodic fever syndrome. The clinical spectrum in a series of 50 patients. International Hyper-IgD Study Group. Medicine (Baltimore) 1994;73:133-44. van der Meer JW, Vossen JM, Radl J, van Nieuwkoop JA, Meyer CJ, Lobatto S, et al. Hyperimmunoglobulinaemia D and periodic fever: a new syndrome. Lancet 1984;1:1087-90. van der Hilst JC, Bodar EJ, Barron KS, Frenkel J, Drenth JP, van der Meer JW, et al. Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine (Baltimore) 2008;87:301-10.
  4. Combemale P, Denis-Thely L, Crozes P, Estival JL, Dupin M, Chouvet B. Auto-inflammatory disease with hyperimmunoglobulinemia D of late onset. Ann Dermatol Venereol 2006;133:369-74. [Abstract] Drenth JP, Cuisset L, Grateau G, Vasseur C, van de Velde-Visser SD, de Jong JG, et al. Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group. Nat Genet 1999;22:178-81.
  5. Houten SM, Kuis W, Duran M, de Koning TJ, van Royen-Kerkhof A, Romeijn GJ, et al. Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome. Nat Genet 1999;22:175-7.
  6. Topaloğlu R, Ayaz NA, Waterham HR, Yüce A, Gumruk F, Sanal O. Hyperimmunoglobulinemia D and periodic fever syndrome; treatment with etanercept and follow-up. Clin Rheumatol 2008;27:1317-20. Steichen O, van der Hilst J, Simon A, Cuisset L, Grateau G. A clinical criterion to exclude the hyperimmunoglobulin D syndrome (mild mevalonate kinase deficiency) in patients with recurrent fever. J Rheumatol 2009;36:1677-81.
  7. Nagashima T, Okazaki H, Yudoh K, Matsuno H, Minota S. Apoptosis of rheumatoid synovial cells by statins through the